+

WO2008038160A3 - Substance à effet sédatif - Google Patents

Substance à effet sédatif Download PDF

Info

Publication number
WO2008038160A3
WO2008038160A3 PCT/IB2007/004218 IB2007004218W WO2008038160A3 WO 2008038160 A3 WO2008038160 A3 WO 2008038160A3 IB 2007004218 W IB2007004218 W IB 2007004218W WO 2008038160 A3 WO2008038160 A3 WO 2008038160A3
Authority
WO
WIPO (PCT)
Prior art keywords
substance
patients
pyrone
gamma
days
Prior art date
Application number
PCT/IB2007/004218
Other languages
English (en)
Other versions
WO2008038160A2 (fr
Original Assignee
Technology Commercialization
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/459,659 external-priority patent/US20060252824A1/en
Application filed by Technology Commercialization filed Critical Technology Commercialization
Publication of WO2008038160A2 publication Critical patent/WO2008038160A2/fr
Publication of WO2008038160A3 publication Critical patent/WO2008038160A3/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Anesthesiology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne une substance à effet sédatif, qui comprend une dose thérapeutiquement efficace d'un gamma-pyrone, tel que l'acide coménique, l'acide méconique, l'acide 5-méthoxy-gamma-pyrone-2-carboxylique et analogues, dans un support pharmaceutiquement acceptable. Administrée selon une posologie quotidienne de 0,05 mg à environ 10 000 mg du principe actif par dose unitaire d'un patient, la substance de l'invention peut servir à traiter divers troubles du système nerveux, par exemple la douleur, l'insomnie, l'anxiété, la névrose, la dépression, ainsi que des symptômes de sevrage chez des patients toxicomanes, en particulier des patients dépendants des opiacés. La substance de l'invention peut être administrée selon plusieurs voies d'administration systémique d'un agent pharmaceutique, notamment l'administration par voie orale, parentérale, transdermique ou transmuqueuse. Pour les patients toxicomanes, le procédé d'administration préféré implique un implant sous-cutané assurant une libération continue d'un principe actif, selon une dose quotidienne efficace, pendant toute la durée du traitement s'étalant entre 5 et 30 jours, de préférence, entre 13 et 20 jours.
PCT/IB2007/004218 2006-07-25 2007-06-21 Substance à effet sédatif WO2008038160A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/459,659 2006-07-25
US11/459,659 US20060252824A1 (en) 2002-03-19 2006-07-25 Substance with sedative effect

Publications (2)

Publication Number Publication Date
WO2008038160A2 WO2008038160A2 (fr) 2008-04-03
WO2008038160A3 true WO2008038160A3 (fr) 2008-07-24

Family

ID=39230613

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2007/004218 WO2008038160A2 (fr) 2006-07-25 2007-06-21 Substance à effet sédatif

Country Status (1)

Country Link
WO (1) WO2008038160A2 (fr)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003079976A2 (fr) * 2002-03-19 2003-10-02 Technology Commercialization Corp. Substance ayant une action sedative

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003079976A2 (fr) * 2002-03-19 2003-10-02 Technology Commercialization Corp. Substance ayant une action sedative
US20060252824A1 (en) * 2002-03-19 2006-11-09 Krylov Boris V Substance with sedative effect

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DERBENEV A V ET AL: "Effects of meconic and comenic acids on slow sodium channels of secondary neurons.", MEMBRANE & CELL BIOLOGY 2000, vol. 13, no. 3, 2000, pages 379 - 387, XP009098978, ISSN: 1023-6597 *
ROGACHEVSKII I V ET AL: "Quantum-chemical study of the equilibrium geometry and electronic structure of certain [gamma]-pyrone derivatives", RUSSIAN JOURNAL OF GENERAL CHEMISTRY, NAUKA/INTERPERIODICA, MO, vol. 76, no. 11, 1 November 2006 (2006-11-01), pages 1820 - 1833, XP019468092, ISSN: 1608-3350 *
V. ROGACHEVSKY, V. B. PLAKHOVA, S. A. PODZOROVA: "METAL-BOUND FORMS OF 4H-PYRAN-4-ONE DERIVATIVES MODULATE NOCICEPTIVE RESPONSES OF SENSORY NEURONS", TECHNOLOGIES OF THE 21ST CENTURY-BOOK OF ABSTRACTS, 27 September 2005 (2005-09-27), pages 77 - 80, XP002477283, Retrieved from the Internet <URL:http://www.infran.ru/meetings/Abstracts-AvH.pdf> [retrieved on 20080418] *

Also Published As

Publication number Publication date
WO2008038160A2 (fr) 2008-04-03

Similar Documents

Publication Publication Date Title
US6271240B1 (en) Methods for improved regulation of endogenous dopamine in prolonged treatment of opioid addicted individuals
JP4898073B2 (ja) 鼻内投与用フェンタニル組成物
CN101534809B (zh) 取代的2-氨基1,2,3,4-四氢化萘在制备预防、减轻和/或治疗各类疼痛的药物中的用途
HK1139871A1 (en) Improvements in and relating to medicinal compositions
WO2003080022A3 (fr) Analgesiques
JP2006231070A5 (fr)
JP5306207B2 (ja) 無針薬物送達デバイスにおけるオピオイド製剤の使用
WO2007098479A3 (fr) Délivrance localisée d&#39;insuline pour guérison osseuse
WO2003079976A3 (fr) Substance ayant une action sedative
MX2009009132A (es) Composiciones medicinales mejoradas que comprenden buprenorfina y naltrexona.
JP5134973B2 (ja) 医薬の組み合わせでの処置方法およびこれに適する医薬の組み合わせ
US20150352040A1 (en) Topical peripheral neuro-affective (tpna) therapy
CA2570474A1 (fr) Compositions comprenant du paracetamol et de l&#39;ibuprofene
JP4173538B2 (ja) 痛みの管理及び解毒のためのケタミンの点鼻及び点眼投与
JP2016505050A5 (fr)
JP2003176227A (ja) 製薬組成物、喫煙を控えている患者の喫煙禁断症状を軽減する方法及び患者の喫煙禁断症状を軽減するキット
CN104758445A (zh) 一种烟叶提取物及其在依赖治疗中的应用
Maseeh et al. A review of smoking cessation interventions
WO2008038160A3 (fr) Substance à effet sédatif
ES2274064T3 (es) Combinacion de principios activos para la terapia medicamentosa de la dependencia a la nicotina.
US20220175755A1 (en) Methods of treating tobacco smoking addiction, and treating nicotine and tobacco smoking addiction
US20160058752A1 (en) Topical peripheral neuro-affective (tpna) therapy for neuropathic conditions
Bentz Clonidine is more effective than placebo for long-term smoking cessation but has side effects/COMMENTARY
RU2008103666A (ru) Способ лечения острой аллергии и устройство для доставки лекарственного средства
Wilken et al. Smoking cessation—part III: pharmacotherapy of smoking cessation

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07859265

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 07859265

Country of ref document: EP

Kind code of ref document: A2

点击 这是indexloc提供的php浏览器服务,不要输入任何密码和下载